Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Leaderboard Analytics
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
MYLAN PHARMACEUTICALS INC. et al v. SANOFI-AVENTIS U.S. LLC et al
Case Number:
2:23-cv-00836
Court:
Nature of Suit:
Judge:
Firms
Companies
Government Agencies
Sectors & Industries:
-
November 21, 2023
FTC Warns Of Harms In Mylan Dispute With Sanofi
Federal trade officials have said improper listings of drugs on the U.S. Food and Drug Administration's catalog of approved pharmaceuticals "can cause significant harm to competition," the latest in an intellectual property fight between Mylan Pharmaceuticals and Sanofi-Aventis.
-
September 18, 2023
Sanofi Slams Mylan's 'Mishmash' Of Claims Over Insulin
Sanofi-Aventis U.S. is asking a Pennsylvania federal court to toss Mylan Pharmaceuticals' claims that Sanofi abused discounts and patent litigation to keep Mylan's generic injectable insulin off the market, arguing Mylan's antitrust complaint amounts to a "mishmash" of allegations that fall short of pleading standards for Sherman Act suits.